What we are funding now
Our ultimate goal is to live in a world without Glycogen Storage Disease.
Your generous contributions are working hard to help us get there.
Beam Therapeutics has initiated a clinical development program in glycogen storage disease type 1a. Beam is using base editing to potentiall correct the causative genetic change in G6PC: initially the R83C variant, which is the most common mutation in GSD1a. Base editing is an emerging class of precision genetic medicines designed to overcome the limitations of existing approaches and expand the potential of genetic medicine. By rewriting a single base, base editors may correct disease-causing point mutations and potentially create life-long cures for patients suffering from serious diseases. Click below to read about their preclinical data.
This template controls the elements:
FOOTER: Footer Title, Footer Descriptions
CUSTOM MENU: Images and columns into header main menu submenu items
* This message is only visible in administrative mode
" ... because every child deserves to be healthy."